| アブストラクト | The primary prophylaxis with filgrastim (FIL) and pegfilgrastim (PEG-F) is recommended to decrease the severity of chemotherapy-induced neutropenia (CIN). The commonly reported adverse drug reactions (ADRs) with FIL and PEG-F is bone pain. ADRs pertaining to FIL and PEG-F were extracted from the European EudraVigilance (EV) database. The Individual Case Safety Reports (ICSRs) obtained from EV database that reported FIL and PEG-F as the suspected drug were analyzed. Registered ADRs (from the groups "General disorders and administration site conditions", "Blood and lymphatic system disorders", "Musculoskeletal and connective tissue disorders" and "Investigations") for FIL and PEG-F were collected from EV database from 2007 to 5 June 2021. The reporting odds ratio (ROR) was used to calculate ICSRs with most common ADRs related to FIL and PEG-F. A total of 17,403 ICSRs described the incidence of most common ADRs of FIL and PEG-F. The commonly reported ADRs for both drugs were pyrexia, bone pain, back pain, neutropenia and febrile neutropenia. The odds ratio of ICSRs belonging to the System Organ Class (SOC) "Investigations" (ROR 1.01 (CI 0.93-1.10)) revealed no significant difference in FIL and PEG-F. However, for the SOCs (General disorders and administration site conditions" and "Musculoskeletal and connective tissue disorders" ((ROR 1.14 (CI 1.06-1.21); ROR 1.21 (CI 1.18-1.32), respectively), an increased reporting probability with PEG-F was found. The authors reported a lower reporting probability for the SOC "Blood and lymphatic system disorders" for FIL versus PEG-F (ROR 0.75 (CI 0.70-0.80)). Our results have demonstrated that the occurrence of bone pain was similar with FIL and PEG-F. For the incidence of pyrexia and back pain, PEG-F was associated with a higher reporting probability as compared to FIL. However, the incidence of neutropenia and febrile neutropenia was higher in FIL compared to PEG-F. Further evaluation of data from real life is needed. |
|---|
| ジャーナル名 | Biology |
|---|
| Pubmed追加日 | 2022/2/26 |
|---|
| 投稿者 | Rastogi, Shruti; Kalaiselvan, Vivekanandan; Bin Jardan, Yousef A; Zameer, Saima; Sarwat, Maryam |
|---|
| 組織名 | Amity Institute of Pharmacy, Amity University, Noida 201313, India.;Indian Pharmacopoeia Commission, Ministry of Health & Family Welfare, Government;of India, Ghaziabad 201002, India.;Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh;11451, Saudi Arabia.;Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI;49503, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/35205206/ |
|---|
